Minor immunophilin binding of tacrolimus and sirolimus metabolites

Clinical Biochemistry

Volumn 33, Issue 1, 2000, Pages 1-6

  Davis, Diane L ^a,b,c   Murthy, Jayasimha N ^a,d   Gallant Haidner, Heather ^e   Yatscoff, Randall W ^e   Soldin, Steven J ^a,b,d  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b CATHOLIC UNIVERSITY OF AMERICA   (United States)

^c SALISBURY UNIVERSITY   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cross reactivity; Immunophilin; Metabolite; Radioreceptor assay; Sirolimus; Tacrolimus

Indexed keywords

DRUG METABOLITE; IMMUNOPHILIN; PROTEIN SUBUNIT; RAPAMYCIN; TACROLIMUS;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG BINDING; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; MIXED LYMPHOCYTE CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RADIORECEPTOR ASSAY;

ANIMALS; ANTI-BACTERIAL AGENTS; CATTLE; CROSS REACTIONS; HUMANS; IMMUNOPHILINS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE CULTURE TEST, MIXED; MOLECULAR WEIGHT; PROTEIN BINDING; RADIOLIGAND ASSAY; SIROLIMUS; TACROLIMUS;

EID: 0034099456     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(99)00080-6     Document Type: Article

References (22)

1. Bierer B.E., Mattila P.S., Standaert R.F., et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 and rapamycin. Proc Natl Acta Sci USA. 87:1990;9231-9235.
2. Dumont F.J., Saruch M.J., Koprak S.L., Melino M.R., Sigal N.H. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK506 and rapamycin. J Immunol. 144:(1):1990;1418-1424.
3. Terada N., Lucas J.J., Szepesi A., Franklin R.A., Takase K., Gelfand E.W. Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells. Biochem Biophys Res Commun. 186:(3):1992;1315-1321.
4. Venkataramanan R, Jain A, Warty VS, et al. Pharmacokinetics of FK506 in transplantation patients. Transplant Proc 1990; 22(1, Suppl 1): 60-3.
5. Venkataramanan R., Jain A., Warty V.S., et al. Pharmacokinetics of FK506 following oral administration a comparison of FK506 and cyclosporine . Transplant Proc. 23:(1):1991;931-933.
6. Kahan B.D., Murgia M.G., Slaton J., Napoli K. Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation. Ther Drug Monit. 17:(6):1995;672-675.
7. Gonschior A., Christians U., Braun F., et al. Measurement of blood concentration of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose the HPLC-MS and microparticle enzyme immunoassay (MEIA). Br J Clin Pharamocol. 38:1994;567-571.
8. Jusko W.J., Thomson A.W., Fung J., et al. Consensus document therapeutic monitoring of tacrolimus (FK506) . Ther Drug Monit. 17:1995;606-614.
9. Oellerich V., Armstrong V.W., Kahan B., et al. Lake Louise Consensus conference on cyclosporin monitoring in organ transplantation report of the consensus panel . Ther Drug Monit. 17:1995;642-654.
10. Yatscoff R.W., Boeckx R., Holt D.W., et al. Consensus guidelines for therapeutic drug monitoring of rapamycin report of the consensus panel . Ther Drug Monit. 17:1995;676-680.
11. Murthy J.N., Davis D.L., Yatscoff R., Soldin S.J. Tacrolimus metabolite cross-reactivity in different tacrolimus assays. Clin Biochem. 31:(8):1998;613-617.
12. Davis DL, Murthy JN, Soldin SJ. Identification of a 5-8 kDa tacrolimus and sirolimus binding immunophilin from calf thymus and Jurkat T cells. In preparation.
13. Murthy J.N., Goodyear N., Soldin S.J. Identification of a 37 kDa tacrolimus, sirolimus and cyclosporine binding immunophilin possessing glyceraldehyde-3-phosphate dehydrogenase activity from Jurkat T cell line. Clin Biochem. 30:1997;129-133.
14. Kuhnt M., Bitsch F., Ponelle M., Fehr T., Sanglier J. Microbial conversion of rapamycin. Enzyme and Microbial Techn. 21:1997;405-412.
15. Christians U., Sattler M., Schiebel H.M., et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos. 20:1992;186-191.
16. Wang C.P., Chan K.W., Schiksinis R.A., Scantina J.A., Sisenwine S.F. High performance liquid chromatographic isolation, spectroscopic characterization and immunosuppressive activities of two rapamycin degradation products. J Liq Chromatogr. 17:1994;3383-3392.
17. Wang C.P., Lim H.K., Chan K.W., Schiksinis R.A., Scantina J.A., Sisenwine S.F. High performance liquid chromatographic isolation, spectroscopic characterization and immunosuppressive activities of three major metabolites from the plasma of rats receiving rapamycin (sirolimus) orally. J Liq Chromatogr. 18:1995;2559-2568.
18. Jusko W.J. Analysis of tacrolimus (FK506) in relation to therapeutic drug monitoring. Ther Drug Monit. 17:1995;596-601.
19. Yatscoff RW, et al. Isotechnika, Inc., Edmonton, Alberta, Canada. submitted.
20. Streit F., Christians U., Schiebel H.M., et al. Sensitive and specific quantitation of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem. 42:1996;1417-1425.
21. Trepanier D.J., Gallant H., Legatt D.F., Yatscoff R.W. Rapamycin distribution, pharmacokinetics and therapeutic range investigations: an update . Clin Biochem. 31:(5):1998;345-351.
22. Gonschior A.K., Christians U., Winkler M., Linck A., Baumann J., Sewing F.K. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. Clin Chem. 42:1996;1426-1432.